MARLBOROUGH, Mass., (May 1, 2019) – Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San Francisco on May 8-11.

Safety and efficacy data from the UNTOUCHED study of the Subcutaneous Implantable Defibrillator System (S-ICD) as well as a pooled analysis of data from the Multicenter Automatic Defibrillator Implantation (MADIT) trials will be presented during late-breaking clinical trial sessions on Friday, May 10. Additional data presentations of interest will highlight:

• safety and efficacy performance outcomes of the POLARx™ Cryoablation Catheter for pulmonary vein isolation;
• real-world results from the NESTed post-approval study of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device;
• additional application of the HeartLogic™ Heart Failure Diagnostic;
• evidence supporting the improved detection of atrial arrythmias in the LUX-Dx™ Insertable Cardiac Monitor.

“This year, we’re eager to present new data further supporting the use of the S-ICD System as a first-line therapy for patients at risk for sudden cardiac death as well as data underscoring the clinical potential of our future technologies including the POLARx cryoballon ablation catheter and the Lux Dx insertable cardiac monitor,” said Dr. Kenneth Stein, senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific. “We are also excited about the presentation of results from MADIT-CHIC, our grant-funded research on the use of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy, as it is one of the first prospective trials to focus on this growing population.”